Physiologically-based pharmacokinetics in drug development and regulatory science.

By M. Rowland, C. Peck, G. Tucker. Annual Review of Pharmacology and Toxicology, 2011

663 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Physiologically based pharmacokinetic modeling in drug discovery and development: A pharmaceutical industry perspective (2015, background): “Applications in the preclinical space include animal or human PK projections, as well as efficacious dose projections, oral absorption, and DDI modeling.(6,35,36) Successful models can inform design and outcomes of formulation, PK, toxicokinetic, or pharmacological studies, thus supporting the three”
Computational Approaches in Preclinical Studies on Drug Discovery and Development (2020, background): “In recent years, PBPK modeling has been substantially improved, making it more widely applicable for the research and development of drugs (Edginton et al., 2008; Rowland et al., 2011; Zhuang and Lu, 2016).”
PBPK models for the prediction of in vivo performance of oral dosage forms. (2014, methodology): “Thereby, PBPK modeling takes into account the factors influencing the absorption, distribution and elimination processes (Rowland et al., 2011).”
PBPK modeling and simulation in drug research and development (2016, background): “A few cases (3) had clinical data available for building and optimizing the final models(22).”